
Cadillac delays in-house F1 power unit debut to 2030
NXTbets Pro | Published On: November 20, 2026
Cadillac Power Unit
Cadillac has pushed back its first in-house Formula 1 power unit to align its debut with the series’ planned move to turbocharged V8 engines. The team will remain a Ferrari customer during the delay, while General Motors continues developing the program from V6 work toward the planned V8 design. The change shifts Cadillac’s power-unit schedule alongside a broader change in Formula 1’s engine rules, rather than introducing its own unit under the current formula. General Motors will be treated as a new manufacturer under the new regulations. Cadillac’s engine facility in Charlotte is scheduled to open Dec. 18, a step in the company’s effort to build its own power-unit operation. The move to a V8 design gives the program a new target, but the final details of the engine package remain unsettled, including the hybrid system and cost cap. Cadillac’s plan now links its in-house engine debut to the timing and shape of the new rules.
Formula 1 Engine Rules
Formula 1 teams, engine manufacturers and officials have reached an agreement in principle on a 2.1-liter turbocharged V8 formula, but the proposal still needs formal approval from the FIA World Motor Sport Council. The planned engines would retain turbochargers while using a smaller hybrid system with an electrical component capped at 200 kilowatts. Half of the available electric power would be reserved for overtake mode. The rules aim to reduce energy starvation and make the cars simpler, cheaper and lighter. The engines are projected to produce about 1,050 brake horsepower in overtake mode and just over 900 in standard running. Their sound is expected to remain closer to current Formula 1 engines than to the louder V8s used from 2006 to 2013. The agreement sets out the direction for the next engine formula, but it does not settle every part of the package. Officials still need to resolve the hybrid system and cost cap before the proposal receives formal approval.